KRAS and colorectal carcinoma: Well after our model finalization (training, + mRNA stability adjustments), and our own experimental verifications, in a very recent paper by Misale et al. [59], these authors demonstrated that, in CRC lines that had become resistant to panErb inhibitors (because of the late appearance of a mutated KRAS), the addition of MEK inhibitors could partially overcome resistance.